School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China.
Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China.
Bioorg Med Chem. 2024 Oct 1;112:117874. doi: 10.1016/j.bmc.2024.117874. Epub 2024 Aug 16.
Gout is an autoinflammatory disorder characterized by the accumulation of monosodium urate crystals in joints and other tissues, representing the predominant type of inflammatory arthritis with a notable prevalence and propensity for severe outcomes. The NLRP3 inflammasome, a member of the pyrin domain-containing NOD-like receptor family, exerts a substantial impact on both innate and adaptive immune responses and serves as a pivotal factor in the pathogenesis of gout. In recent years, there has been significant academic and industrial interest in the development of NLRP3-targeted small molecule inhibitors as a promising therapeutic approach for gout. To assess the advancements in NLRP3 inflammasome inhibitors for gout treatment, this review offers a comprehensive analysis and evaluation of current clinical candidates and other inhibitors targeting NLRP3 inflammasome from a chemical structure standpoint, with the goal of identifying more efficacious options for clinical management of gout.
痛风是一种自身炎症性疾病，其特征是单钠尿酸盐晶体在关节和其他组织中的积累，代表了一种主要的炎症性关节炎类型，具有显著的流行率和严重后果的倾向。NLRP3 炎性体是 pyrin 结构域包含的 NOD 样受体家族的成员，对先天和适应性免疫反应都有很大的影响，是痛风发病机制中的关键因素。近年来，人们对 NLRP3 靶向小分子抑制剂的开发产生了浓厚的学术和工业兴趣，认为这是一种治疗痛风的有前途的治疗方法。为了评估 NLRP3 炎性体抑制剂在痛风治疗中的进展，本综述从化学结构的角度对目前的临床候选物和其他靶向 NLRP3 炎性体的抑制剂进行了全面的分析和评价，旨在为痛风的临床治疗找到更有效的方法。
